Docetaxel
Small molecule targets AR, BCL2 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 13 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | DOCETAXEL | — | 2014-07-10 – 2019-01-08 | fda.gov ↗ |
| Label expansions (9) | US (FDA) | TAXOTERE | — | 1998-06-22 – 2010-05-13 | fda.gov ↗ |
| Approved | US (FDA) | TAXOTERE | — | 1996-05-14 | fda.gov ↗ |
| Approved | EU (EMA) | Taxotere | — | 1995-11-27 | europa.eu ↗ |
Trials 1,576 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 08 trials | ||||||
| Phase 0 | NCT07516704 | Apr 2026 → Dec 2027 expected | prostate cancer | Zhongda Hospital | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06204614 | Jun 2024 → Jul 2028 expected | infiltrating bladder urothelial carcinoma | Brigham and Women's Hospital | Enrolling by invitation | No outcome recorded |
| Phase 0 | NCT06208033 | Jan → Oct 2024 | non-small cell lung carcinoma | Fujian Cancer Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT05713578 | Mar 2023 → Feb 2026 overdue | — | Qilu Hospital of Shandong University | Recruiting | No outcome recorded |
| Phase 0 | NCT03358563 | Jan 2018 → Aug 2021 | prostate cancer | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 0 | NCT02568033 | Oct 2013 → Oct 2017 | non-small cell lung carcinoma | The Cooper Health System | Unknown | No outcome recorded |
| Phase 0 | NCT01275183 | Dec 2010 → Apr 2015 | head and neck cancer | New Mexico Cancer Research Alliance | Completed | No outcome recorded |
| Phase 0 | NCT00949247 | Dec 2009 → Jan 2013 | breast cancer | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1204 trials · 3 met primary | ||||||
| Phase 1 | NCT06724042 | Jun 2026 → Jun 2029 expected | metastatic neoplasm, neoplasm | InSilico Medicine | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07316686 | Jun → Sep 2026 overdue | prostate adenocarcinoma | Cancer Institute of the State of São Paulo | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05296005 | Dec 2025 | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Ohio State University Comprehensive Cancer Center | Withdrawn | No outcome recorded |
| Phase 1 | NCT07059299 | Dec 2025 → Aug 2027 expected | esophageal adenocarcinoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Recruiting | No outcome recorded |
| Phase 1 | NCT05733689 | Jun 2025 → Jun 2027 expected | gastroesophageal adenocarcinoma | University of California, Irvine | Recruiting | No outcome recorded |
| Phase 1 | NCT06769425 | May 2025 → May 2026 overdue | female breast carcinoma, gastric cancer, ovarian cancer, prostate cancer +1 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT06925659 | May 2025 → Jun 2026 overdue | — | Qilu Pharmaceutical (Hainan) Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07007988 | Apr 2025 → Jun 2027 expected | peritoneal neoplasm | Jiangsu Simcere Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT06868732 | Apr 2025 → Jun 2028 expected | non-small cell lung carcinoma | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Recruiting | No outcome recorded |
| Phase 1 | NCT06120075 | Jan 2024 → Apr 2026 | — | Arcus Biosciences, Inc. | Completed | No outcome recorded |
| Show all 204 trials opens the full record — a long page | ||||||
| Phase 1/2137 trials · 3 missed | ||||||
| Phase 1/2 | NCT07850973 | Mar 2027 → Dec 2029 expected | malignant germ cell tumor | M.D. Anderson Cancer Center | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07472647 | Feb 2026 → Feb 2029 expected | non-small cell lung carcinoma, small cell lung carcinoma | Shanghai JMT-Bio Inc. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06682780 | Sep 2025 → Dec 2028 expected | neoplasm | LaNova Medicines Limited | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07070440 | Jul 2025 → Jun 2027 expected | non-small cell lung carcinoma | Dizal Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06949761 | Jun 2025 → Sep 2026 overdue | neoplasm | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06943820 | May 2025 → Dec 2026 expected | colorectal adenocarcinoma, head and neck squamous cell carcinoma, non-small cell lung carcinoma | Akeso | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06879717 | Apr 2025 → Jan 2027 expected | non-small cell lung carcinoma | iOnctura | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06704191 | Apr 2025 → Dec 2027 expected | bladder carcinoma in situ | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06732856 | Apr 2025 → Dec 2027 expected | gastric cancer | Asan Medical Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06568094 | Sep 2024 → Dec 2026 expected | prostate cancer | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Show all 137 trials opens the full record — a long page | ||||||
| Phase 2897 trials · 21 met primary · 33 missed | ||||||
| Phase 2 | NCT06227065 | Dec 2026 → Nov 2030 expected | non-invasive bladder urothelial carcinoma | Hospital Centre Biel/Bienne | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07645326 | Dec 2026 → Aug 2032 expected | metastatic prostate carcinoma | Georgetown University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07828873 | Nov 2026 → Sep 2029 expected | gastroesophageal adenocarcinoma | The First Affiliated Hospital of Zhengzhou University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07801898 | Sep 2026 → Sep 2028 expected | invasive breast carcinoma | The Second Hospital of Anhui Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07603375 | Sep 2026 → Aug 2029 expected | esophageal adenocarcinoma | Duke University | Recruiting | No outcome recorded |
| Phase 2 | NCT07645846 | Jul 2026 → Aug 2028 expected | nasal cavity and paranasal sinus carcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07669415 | Jun 2026 → Dec 2027 expected | neoplasm | LaNova Medicines Limited | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06972615 | May 2026 → Dec 2029 expected | urinary bladder carcinoma | BLATAM | Recruiting | No outcome recorded |
| Phase 2 | NCT07776639 | May 2026 → Sep 2027 expected | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Yongxu Jia | Active not recruiting | No outcome recorded |
| Phase 2 | NCT07528274 | May 2026 → Dec 2027 expected | non-small cell lung carcinoma | Tianjin Medical University Cancer Institute and Hospital | Recruiting | No outcome recorded |
| Show all 897 trials opens the full record — a long page | ||||||
| Phase 2/338 trials · 5 met primary · 4 missed | ||||||
| Phase 2/3 | NCT06028737 | Mar 2025 → Apr 2027 expected | gastric adenocarcinoma, gastroesophageal cancer, gastroesophageal junction adenocarcinoma | Ukrainian Society of Clinical Oncology | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06279130 | Jan 2024 → Jan 2029 expected | — | The Netherlands Cancer Institute | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05189067 | Jan 2022 → Jan 2025 | HER2 positive breast carcinoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 2/3 | NCT04138992 | Aug 2020 → May 2021 | — | Air Force Military Medical University, China | Unknown | No outcome recorded |
| Phase 2/3 | NCT03908372 | Jun 2019 → May 2021 | nasopharyngeal squamous cell carcinoma | Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
| Phase 2/3 | NCT03879122 | Feb 2019 → Jul 2023 | metastatic prostate carcinoma | Spanish Oncology Genito-Urinary Group | Unknown | No outcome recorded |
| Phase 2/3 | NCT03600831 | Aug 2018 → May 2022 | esophageal squamous cell carcinoma | Huai'an First People's Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT03691454 | Jun 2018 → Sep 2026 overdue | gastric adenocarcinoma | Peking University | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT02923258 | Apr 2018 → Feb 2022 | oral cavity squamous cell carcinoma | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Completed | Missed primary |
| Phase 2/3 | NCT03373708 | Dec 2017 → Dec 2019 | breast cancer | Zhiyong Yu | Unknown | No outcome recorded |
| Phase 2/3 | NCT03349177 | Nov 2017 → Nov 2019 | breast cancer | Zhiyong Yu | Unknown | No outcome recorded |
| Phase 2/3 | NCT03178552 | Sep 2017 → Jun 2027 expected | non-small cell lung carcinoma | Hoffmann-La Roche | Active not recruiting | Mixed |
| Phase 2/3 | NCT03070886 | Apr 2017 → Oct 2025 overdue | prostate adenocarcinoma | NRG Oncology | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT02780778 | May 2016 → Dec 2017 | non-small cell lung carcinoma | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT02641847 | Jan 2016 → Dec 2023 overdue | female breast carcinoma, triple-negative breast carcinoma | Fudan University | Active not recruiting | Met primary |
| Phase 2/3 | NCT02651610 | Dec 2015 → Dec 2017 | breast cancer | Peregrine Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT02326285 | Nov 2015 → Mar 2017 | non-small cell lung carcinoma | AIO-Studien-gGmbH | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2/3 | NCT03258320 | Jan 2015 → Dec 2026 expected | prostate cancer | Shanghai Jiao Tong University School of Medicine | Recruiting | No outcome recorded |
| Phase 2/3 | NCT02965378 | Oct 2014 → Jan 2017 | squamous cell lung carcinoma | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 2/3 | NCT02785939 | Sep 2014 → Jun 2017 | non-small cell squamous lung carcinoma | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 2/3 | NCT01999933 | Nov 2013 → Nov 2016 | cervical cancer, poisoning | Mei Shi | Unknown | No outcome recorded |
| Phase 2/3 | NCT01810913 | Mar 2013 → Jan 2027 | hypopharynx squamous cell carcinoma, laryngeal squamous cell carcinoma, oral cavity squamous cell carcinoma, oropharynx squamous cell carcinoma | National Cancer Institute (NCI) | Suspended | No outcome recorded Stop: Enrollment |
| Phase 2/3 | NCT01774578 | Feb 2013 → May 2016 | non-small cell lung carcinoma | NewLink Genetics Corporation | Terminated | No outcome recorded |
| Phase 2/3 | NCT01603420 | Jul 2012 → May 2014 | prostate cancer | Proton Collaborative Group | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2/3 | NCT01779206 | May 2012 → Sep 2019 | breast cancer | West German Study Group | Completed | Met primary |
| Phase 2/3 | NCT01434394 | Aug 2011 → Oct 2014 | chemotherapy-induced toxicity, oral cavity cancer, oropharyngeal carcinoma | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| Phase 2/3 | NCT01216644 | Aug 2010 → Mar 2017 | gastric cancer | Krankenhaus Nordwest | Completed | Met primary |
| Phase 2/3 | NCT01065870 | Dec 2009 → Dec 2014 | pancreas disorder | Columbia University | Unknown | No outcome recorded |
| Phase 2/3 | NCT01924819 | Sep 2009 → Dec 2026 expected | gastric cancer | Australasian Gastro-Intestinal Trials Group | Active not recruiting | Missed primary |
| Phase 2/3 | NCT01150513 | Jun 2009 → Jan 2016 | breast cancer | Chinese Academy of Medical Sciences | Completed | Met primary |
| Phase 2/3 | NCT01542931 | Jan 2008 → Dec 2015 | oral cavity squamous cell carcinoma | Shanghai Jiao Tong University School of Medicine | Completed | Missed primary |
| Phase 2/3 | NCT00268476 | Jul 2005 → Mar 2026 overdue | prostate cancer | Medical Research Council | Active not recruiting | Mixed |
| Phase 2/3 | NCT00201435 | Mar 2005 → Jan 2008 | breast neoplasm | Norwegian Breast Cancer Group | Completed | No outcome recorded |
| Phase 2/3 | NCT00525642 | Jun 2003 → Jun 2015 | breast cancer | Fudan University | Unknown | No outcome recorded |
| Phase 2/3 | NCT00261703 | Dec 2002 → Jul 2010 | head and neck neoplasm | Sanofi | Completed | Missed primary |
| Phase 2/3 | NCT00030641 | Oct 2001 → ? | lung cancer | Genta Incorporated | Unknown | No outcome recorded |
| Phase 2/3 | NCT00290966 | Oct 1998 → May 2003 | gastric neoplasm | Sanofi | Completed | Met primary |
| Phase 2/3 | NCT00401323 | Jan 1998 → Jun 2003 | head and neck squamous cell carcinoma, metastatic neoplasm | Sanofi | Completed | No outcome recorded |
| Phase 3236 trials · 32 met primary · 43 missed | ||||||
| Phase 3 | NCT07464145 | Feb 2027 → Dec 2029 expected | non-invasive bladder urothelial carcinoma | Relmada Therapeutics, Inc. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07591467 | Sep 2026 → Sep 2036 expected | hereditary neoplastic syndrome, prostate cancer, prostate neuroendocrine neoplasm | Gustave Roussy, Cancer Campus, Grand Paris | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07805135 | Aug 2026 → Jun 2028 expected | Her2-receptor negative breast cancer | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07371897 | Jun 2026 overdue | head and neck squamous cell carcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07526792 | Jun 2026 → Jun 2029 expected | urothelial carcinoma | CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07333066 | Jun 2026 → Mar 2030 expected | metastatic prostate carcinoma | Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD | Recruiting | No outcome recorded |
| Phase 3 | NCT07313891 | May 2026 → Sep 2029 | non-invasive bladder urothelial carcinoma | Relmada Therapeutics, Inc. | Withdrawn | No outcome recorded |
| Phase 3 | NCT07402538 | Feb 2026 → Dec 2028 expected | oral cavity cancer, oropharyngeal carcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06937905 | Feb 2026 → Feb 2029 expected | neuroendocrine carcinoma | French Cooperative Thoracic Intergroup | Recruiting | No outcome recorded |
| Phase 3 | NCT07225946 | Dec 2025 → Nov 2027 expected | castration-resistant prostate carcinoma | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Show all 236 trials opens the full record — a long page | ||||||
| Phase 420 trials · 1 met primary | ||||||
| Phase 4 | NCT06578299 | Aug 2024 → Mar 2026 overdue | breast cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05843292 | Jul 2023 → Dec 2024 overdue | triple-negative breast carcinoma | Shanghai Jiao Tong University School of Medicine | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT04137640 | Jul 2021 → Nov 2025 | breast cancer | Shengjing Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04766827 | Dec 2020 → Nov 2021 | head and neck squamous cell carcinoma | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04031885 | Aug 2019 → Aug 2020 | breast cancer | Eli Lilly and Company | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT03799601 | Mar → Dec 2019 | non-small cell lung carcinoma | Tongji Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03069820 | Feb 2017 → Jan 2018 | drug-induced liver injury | Second Affiliated Hospital of Nanchang University | Unknown | No outcome recorded |
| Phase 4 | NCT02502864 | Feb 2016 → Sep 2017 | female breast carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT02484677 | Jul 2015 → Jan 2017 | head and neck cancer | Assistance Publique Hopitaux De Marseille | Completed | No outcome recorded |
| Phase 4 | NCT02513342 | Mar 2015 → Oct 2017 | squamous cell lung carcinoma | Nanjing NingQi Medicine Science and Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase 4 | NCT02283424 | Oct 2014 → Oct 2017 | neoplastic disease or syndrome | Chinese PLA General Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02031601 | Jan 2014 → Dec 2016 | non-small cell lung carcinoma | Qilu Hospital of Shandong University | Unknown | Met primary |
| Phase 4 | NCT01665417 | Aug 2012 → Jul 2017 | adenocarcinoma, non-small cell lung carcinoma | Betta Pharmaceuticals Co., Ltd. | Unknown | No outcome recorded |
| Phase 4 | NCT01660542 | Apr 2011 → Jun 2015 | female breast carcinoma | Yonsei University | Completed | No outcome recorded |
| Phase 4 | NCT01301729 | Mar 2011 → Jul 2014 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 4 | NCT00774241 | Jan 2010 → Nov 2013 | breast cancer | Hoffmann-La Roche | Withdrawn | No outcome recorded |
| Phase 4 | NCT00883675 | May 2009 → Sep 2012 | non-small cell lung carcinoma | Michael Mann | Completed | No outcome recorded |
| Phase 4 | NCT00280098 | Jan 2006 → Oct 2007 | prostate neoplasm | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00127933 | Aug 2005 → Apr 2009 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 4 | NCT00772681 | Oct 2004 → Mar 2008 | head and neck neoplasm | Sanofi | Completed | No outcome recorded |
| Phase not applicable34 trials | ||||||
| — | NCT07546383 | Apr 2026 → Dec 2027 expected | head and neck squamous cell carcinoma | The Second Affiliated Hospital of Hainan Medical University | Recruiting | No outcome recorded |
| — | NCT07172685 | Jul 2025 → Jun 2026 overdue | prostate cancer | Qilu Hospital of Shandong University | Recruiting | No outcome recorded |
| — | NCT06576635 | Dec 2024 → Sep 2026 overdue | non-small cell lung carcinoma | University of Illinois at Chicago | Recruiting | No outcome recorded |
| — | NCT07112209 | Nov 2023 → Jun 2027 expected | metastatic prostate carcinoma | Zhujiang Hospital | Enrolling by invitation | No outcome recorded |
| — | NCT05622474 | Nov 2022 → Dec 2025 overdue | nasopharyngeal carcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| — | NCT05494190 | Nov 2022 → Nov 2027 expected | hypopharyngeal carcinoma | Eye & ENT Hospital of Fudan University | Recruiting | No outcome recorded |
| — | NCT06234137 | Nov 2021 → Jul 2025 overdue | breast cancer | Wang Ouchen | Recruiting | No outcome recorded |
| — | NCT05050760 | Sep 2021 → Dec 2023 | esophageal squamous cell carcinoma | Xijing Hospital | Unknown | No outcome recorded |
| — | NCT05656079 | Jul 2021 → Sep 2024 | breast cancer | Shanghai Pudong Hospital | Unknown | No outcome recorded |
| — | NCT04886193 | Apr 2021 → May 2022 | gastric cancer | Guangdong Provincial Hospital of Traditional Chinese Medicine | Unknown | No outcome recorded |
| — | NCT05671900 | Apr 2020 → Jun 2024 | non-invasive bladder urothelial carcinoma | Clinical Hospital Centre Zagreb | Unknown | No outcome recorded |
| — | NCT04220398 | Jan 2020 → Dec 2022 | chemotherapy-induced toxicity, prostate carcinoma | RenJi Hospital | Unknown | No outcome recorded |
| — | NCT04174079 | Dec 2019 → May 2029 expected | esophageal squamous cell carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| — | NCT06864533 | Sep 2019 → Sep 2026 overdue | prostate cancer | Peking University First Hospital | Recruiting | No outcome recorded |
| — | NCT03847818 | Mar 2019 → Mar 2020 | HER2 positive breast carcinoma | Shandong University | Unknown | No outcome recorded |
| — | NCT03566576 | Jul → Sep 2018 | non-small cell lung carcinoma | Fujian Cancer Hospital | Unknown | No outcome recorded |
| — | NCT03489616 | Jan 2018 → Jul 2019 | non-small cell lung carcinoma | Shandong Cancer Hospital and Institute | Unknown | No outcome recorded |
| — | NCT02358863 | Feb 2015 → Nov 2016 | esophageal cancer, gastric cancer | Georgetown University | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT03221881 | Jan 2015 → Apr 2017 | breast cancer | Hebei Medical University Fourth Hospital | Completed | No outcome recorded |
| — | NCT02145078 | Jun 2014 → Jun 2015 | non-small cell lung carcinoma | Barbara Ann Karmanos Cancer Institute | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT01958580 | Sep 2013 → Feb 2017 | leiomyosarcoma of the corpus uteri | Albert Einstein College of Medicine | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT01295086 | Mar 2011 → Nov 2014 | adenocarcinoma | Odense University Hospital | Completed | No outcome recorded |
| — | NCT00911716 | Oct 2008 → Jul 2010 | breast cancer | Cancer Trials Ireland | Completed | No outcome recorded |
| — | NCT01530295 | Jul 2008 → Jul 2012 | prostate cancer | Hanjong Ahn | Unknown | No outcome recorded |
| — | NCT00675597 | May 2008 → Feb 2012 | lung cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| — | NCT00502463 | Oct 2007 → Jan 2010 | head and neck cancer | Austrian South Oncology Group | Completed | No outcome recorded |
| — | NCT00310089 | Jan 2006 → Jul 2007 | breast cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| — | NCT00883480 | Jun 2005 → Jan 2008 | non-small cell lung carcinoma | Spanish Lung Cancer Group | Completed | No outcome recorded |
| — | NCT00159471 | Feb 2005 → Jun 2006 | malignant pancreatic neoplasm | University of Southern California | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT00870714 | Sep 2004 → Sep 2010 | prostate cancer | Kansas City Veteran Affairs Medical Center | Unknown | No outcome recorded |
| — | NCT00079170 | Jan 2004 → Oct 2007 | breast cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| — | NCT00156312 | Jul 2003 → May 2005 | breast cancer | University of Michigan Rogel Cancer Center | Completed | No outcome recorded |
| — | NCT00256789 | Sep 2002 → Dec 2003 | non-small cell lung carcinoma | Clinical Oncology Research Associates | Completed | No outcome recorded |
| — | NCT00614835 | Aug 2001 → Feb 2006 | leiomyosarcoma, uterine cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase not stated2 trials | ||||||
| — | NCT04060628 | — | urinary system neoplasm | NanOlogy, LLC | No longer available | No outcome recorded |
| — | NCT01216124 | — | triple-negative breast carcinoma | Fudan University | Available | No outcome recorded |
| Comparator or background therapy1,035 trials | ||||||
| Phase 0 | NCT03387553 Background | Jun 2018 → Aug 2023 | HER2 positive breast carcinoma, female breast carcinoma, invasive breast carcinoma, male breast carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 1 | NCT07700420 Background | Aug 2026 → Oct 2027 expected | esophageal cancer, gastroesophageal cancer | University of Texas Southwestern Medical Center | Recruiting | No outcome recorded |
| Phase 1 | NCT07699757 Background | Jul 2026 → Apr 2029 expected | non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Haisco Pharmaceutical Group Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06978062 Background | Feb 2026 → Sep 2028 expected | gastroesophageal cancer | European Organisation for Research and Treatment of Cancer - EORTC | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07358806 Background | Dec 2025 → Dec 2027 expected | breast cancer, gastroesophageal cancer, head and neck cancer, non-small cell lung carcinoma +1 | Oscotec Inc. | Recruiting | No outcome recorded |
| Show all 1,035 trials opens the full record — a long page | ||||||
Press releases naming this drug 64 releases
Evidence & citations 29 cited values
Every value below carries the sentence it was read from. 2,624 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Docetaxel | “Option 1: Docetaxel and carboplatin once every 3 weeks for 6 cycles; Option 2: Doxorubicin plus cyclophosphamide once every 3 weeks for 4 cycles, followed by a taxane...” NCT05415215 ↗2556“Docetaxel will be administered as an IV dose of 75 milligrams per square meter (mg/m\^2) on day 1 of cycle 1 (1 cycle length = 21 days), and 75 mg/m\^2 (up to 100 mg/m\^2 as...” NCT03811418 ↗ “Any of the following single-agent chemotherapy may be given at the discretion of the investigator, with a cycle length not to exceed four weeks: Capecitabine, Vinorelbine,...” NCT01156753 ↗ “Patients receive Neoadjuvant Docetaxel (75mg/m2 on day1 03:30-04:30) and cisplatin (75mg/m2 on day 1-5 10:00-22:00) and 5-FU(750mg/m2 on day 1-5 22:00-10:00) every 21days for...” NCT03604965 ↗ “Squamous cell carcinoma: Paclitaxel (175mg/m²) or Docetaxel (60-75 mg/m²) or Nab-paclitaxel (260mg/m²) plus Carboplatin (AUC=5)/Cisplatin (75 mg/m²) (to be determined by...” NCT07608159 ↗ “An Open-label, Randomized Study to Evaluate the Effect of Tarceva, Compared With Alimta (Pemetrexed) or Taxotere (Docetaxel),on Survival in Patients With Advanced, Recurrent or...” NCT00556322 ↗ “Acceptable histology-specific PDC regimens include carboplatin plus paclitaxel or nab-paclitaxel (any histology), carboplatin/cisplatin plus pemetrexed (nonsquamous),...” NCT06865339 ↗ “A1: docetaxel 60mg/m2 on Day 1 vinorelbine 20mg/m2 on Day 1 and Day 8 (DV) A2: gemcitabine 1000mg/m2 on Day 1 vinorelbine 25mg/m2 on Day 1 and Day 8 (GV) A3: docetaxel 75mg/m2...” NCT01648517 ↗ “Docetaxel 75 mg/m2, day 1 Epirubicin 80 mg/m2, day 1 Cyclophosphamide 500 mg/m2, day 1 Navelbine 25 mg/M2 in 250 cc NS over 60 min on day 1 and day 8 Bevacizumab 5 mg/kg in 100...” NCT00830544 ↗ “The Pharmacy of The Netherlands Cancer Institute has developed a new oral formulation of docetaxel (ModraDoc006), which contains a spray dried docetaxel powder resulting in an...” NCT05242926 ↗ “This study was designed to evaluate the efficacy and safety of combined zoledronic acid and docetaxel/carboplatin in patients with non-small cell lung cancer (NSCLC) as...” PMID 19493585 ↗ Jun 2009 |
| Known as | BIND-014 | “BIND-014 (Docetaxel Nanoparticles for Injectable Suspension)” NCT01792479 ↗1“BIND-014 (Docetaxel Nanoparticles for Injectable Suspension)” NCT02283320 ↗ |
| Known as | CPC634 | “Efficacy Study of CPC634 (CriPec® Docetaxel) in Platinum Resistant Ovarian Cancer” NCT03742713 ↗ |
| Known as | CriPec docetaxel | “Efficacy Study of CPC634 (CriPec® Docetaxel) in Platinum Resistant Ovarian Cancer” NCT03742713 ↗1“CriPec® docetaxel” NCT02442531 ↗ |
| Known as | DCT | “METHODS: Forty (40) chemotherapy-naive patients with unresectable LAPC were randomly assigned (1:1) to either continuous fluorouracil (5-FU) 200 mg/m(2)/day (protracted IV) and...” PMID 21943032 ↗ Sep 2011 |
| Known as | DOC | “Participants with human epidermal growth factor receptor 2 (HER2)-positive MBC will receive docetaxel (Doc) 75 milligrams per square meter (mg/m\^2) intravenous (IV) infusion on Day 1” NCT00934856 ↗4“The study is to evaluate the effect of amrubicin (AMR) compared to docetaxel (DOC) in the treatment of non-small cell lung cancer (NSCLC).” NCT01207011 ↗ “Participants received docetaxel (Doc) intravenously starting at 75 mg/m\^2 (1 hour) once every 3 weeks on Day 1 of each cycle.” NCT02393248 ↗ “Docetaxel 75 mg/m² body surface area i.v. (Doc)” NCT02181101 ↗ “Drug: Docetaxel (DOC)” NCT02512315 ↗ |
| Known as | Docetaxel (Taxotere, Sanofi-Aventis Inc.) | “Docetaxel (Taxotere®, Sanofi-Aventis Inc.)” NCT00695994 ↗ |
| Known as | docetaxel (Taxotere, Sanofi-Aventis, FR) | “docetaxel (Taxotere, Sanofi-Aventis, FR)” NCT04999332 ↗ |
| Known as | Docetaxel (Taxotere○R, company: Sanofi-Avantis | “Docetaxel (Taxotere○R, company: Sanofi-Avantis” NCT01558011 ↗ |
| Known as | Docetaxel anhydrous, Docetaxel | “Docetaxel anhydrous, Docetaxel” NCT01019941 ↗ |
| Known as | Docetaxel Injection， Hengrui Medicine | “Docetaxel Injection， Hengrui Medicine” NCT01889303 ↗ |
| Known as | docetaxel(tyxant) | “docetaxel(tyxant)” NCT01019798 ↗ |
| Known as | Docetaxel, Sanofi-Aventis | “Docetaxel, Sanofi-Aventis” NCT01479036 ↗ |
| Known as | docetaxel, taxotere | “Docetaxel (Taxotere®)” NCT00675545 ↗15“Docetaxel (Taxotere)” NCT00659269 ↗ “Docetaxel (taxotere)” NCT00166881 ↗ “Docetaxel (Taxotere)” NCT00206466 ↗ “Docetaxel - Taxotere” NCT01648517 ↗ “docetaxel (Taxotere)” NCT00630110 ↗ “Docetaxel (taxotere)” NCT01312350 ↗ “Docetaxel (Taxotere)” NCT01746277 ↗ “Docetaxel (Taxotere)” NCT00052169 ↗ “Docetaxel (Taxotere)” NCT01181401 ↗ “Docetaxel= Taxotere®” NCT00525642 ↗ |
| Known as | Docetaxel-PNP | “Docetaxel-PNP, Polymeric Nanoparticle Formulation of Docetaxel” NCT01103791 ↗ |
| Known as | DTX | “In this paper, amine-functionalized polyacrylamide nanogels (PAm-NH2) loaded with docetaxel (DTX) were evaluated as a mucoadhesive and sustained intravesical drug delivery...” PMID 25772330 ↗ Mar 20153“Docetaxel (DTX) has a pharmacokinetic advantage after intraperitoneal（IP）delivery which is hundreds of times higher than systemic administration.” NCT02779608 ↗ “Docetaxel (DTX) has demonstrated activity in HNSCC and SGC.” NCT07667400 ↗ “Combination of Docetaxel (DTX) and Epirubicin (EPI)” NCT02392845 ↗ |
| Known as | HHT | “Docetaxel (HHT) 2.5mg/㎡/day, days 3-7” NCT05893472 ↗ |
| Known as | ModraDoc006 | “Currently, treatment with ModraDoc006/r (i.e. oral docetaxel as tablets of 10 mg combined with a ritonavir dose of 100 mg) has been evaluated in several clinical trials at the NKI.” NCT05084456 ↗4“Patients will receive oral docetaxel (as ModraDoc006 10 mg tablets) and ritonavir (100 mg tablet) once- or bi-daily, once a week in a fasted condition.” NCT03150368 ↗ “Treatment with twice daily once weekly (BIDW) ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets” NCT03890744 ↗ “Treatment with twice daily once weekly (BIDW) ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets” NCT04028388 ↗ “Absorption and Excretion of Docetaxel (as ModraDoc 006 Tablets) After Oral Administration in Combination With Ritonavir” NCT05242926 ↗ |
| Known as | Monotaxel | “Docetaxel(Monotaxel®) after Doxorubicin plus Cyclophosphamide” NCT01660542 ↗ |
| Known as | NanoDoce | “NanoDoce (sterile nanoparticulate docetaxel) Powder for Suspension” NCT04260360 ↗1“NanoDoce (sterile nanoparticulate docetaxel) Powder for Suspension” NCT04060628 ↗ |
| Known as | NSC 628503 | “Randomized Phase II Trial of Herceptin (NSC 688097) and Weekly Docetaxel (NSC 628503) in Androgen-Independent (Horomone Refractory) Adenocarcinoma of the Prostate (CaP)” NCT00005857 ↗2“Docetaxel (NSC-628503) And Vinorelbine (NSC-608210) Plus Filgrastim (NSC-614629) With Weekly Trastuzumab (NSC-688097) For HER-2 Positive, Stage IV Breast Cancer” NCT00041067 ↗ “A Phase II Evaluation of Weekly Docetaxel (NSC #628503) in the Treatment of Recurrent or Persistent Endometrial Carcinoma” NCT00085332 ↗ |
| Known as | Taxotere | “This is a research study which aims to improve the way that doctors determine the dose of chemotherapy given to patients. Right now, chemotherapy is determined by a patient's...” NCT00148070 ↗147“A Randomized, Open-Label, Parallel Group, International, Multicenter, Phase III Study of Oral ZD1839 (IRESSA®) Versus Intravenous Docetaxel (TAXOTERE®) in Patients With Locally...” NCT00076388 ↗ “Docetaxel (currently marketed as Taxotere®) is an anti-microtubule agent that prevents cell division by promoting the assembly and stabilization of microtubules and is used for...” NCT01151384 ↗ “To detect a statistically significant increase in time to progression (TTP) of disease for the test group (Taxotere® \[Docetaxel\] combined with cisplatin and 5-fluorouracil...” NCT00811447 ↗ “with cisplatin 75 mg/m(2) and docetaxel (Taxotere) 75 mg/m(2) on days 1 and 22, followed by radiotherapy of 45 Gy (25 x 1.8 Gy) and concurrent chemotherapy comprising cisplatin...” PMID 19465425 ↗ May 2009 “A Randomized Phase III Multicenter Trial of Neoadjuvant Docetaxel (Taxotere) Plus Cisplatin Plus 5-Fluorouracil Versus Neoadjuvant Cisplatin Plus 5-Fluorouracil in Patients...” NCT00003888 ↗ “A Multicenter Randomized Phase II Study Evaluating The Activity And Tolerability Of Three Different Combinations Of Docetaxel (Taxotere) And Irinotecan (Campto) As Second Line...” NCT00139711 ↗ “A Randomized Cost-minimization Trial Comparing Pemetrexed (Alimta®) Versus Docetaxel (Taxotere®) as Second Line Treatment in Advanced Non Small Cell Lung Cancer (NSCLC): Study...” NCT00284778 ↗ “This clinical trial is designed to study whether docetaxel (Taxotere) helps reduce the risk of relapse in patients with prostate cancer who have had their prostate removed by...” NCT00069888 ↗ “The purpose of this study is to determine the effectiveness of the combination of the two drugs, docetaxel (Taxotere®) and carboplatin (Paraplatin®) followed by radiation...” NCT00285415 ↗ “Docetaxel (currently marketed as Taxotere) is an anti-microtubular network agent and is one of the most active agents in the treatment of metastatic castrate resistant prostate...” NCT01188408 ↗ |
| Known as | Taxotere (Docetaxel) | “Taxotere® (docetaxel)” NCT00365365 ↗4“Taxotere (Docetaxel)” NCT00845884 ↗ “Taxotere (docetaxel)” NCT00517829 ↗ “Taxotere (Docetaxel)” NCT00801801 ↗ “Taxotere (Docetaxel)” NCT00636441 ↗ |
| Known as | TXT | “preoperative or postoperative docetaxel (TXT) following 4 courses of preoperative AC.” NCT00002707 ↗3“Docetaxel (TXT) 75 mg/m2, given as a 1h i.v. infusion on day 1” NCT01640782 ↗ “Docetaxel (TXT) + Gemcitabine (GEM)” NCT03121833 ↗ “TXT(Taxotere)” NCT05871918 ↗ |
| Known as | XRP6976 | “DOCETAXEL(XRP6976) + MODAFINIL” NCT00917748 ↗10“XRP6976 (Docetaxel/Taxotere)” NCT00273546 ↗ “Docetaxel (XRP6976)” NCT01308567 ↗ “Docetaxel (XRP6976)” NCT01515748 ↗ “docetaxel (XRP6976)” NCT00401323 ↗ “Docetaxel (XRP6976)” NCT01148615 ↗ “DOCETAXEL (XRP6976)” NCT01718353 ↗ “docetaxel (XRP6976)” NCT00723086 ↗ “DOCETAXEL(XRP6976)” NCT00916097 ↗ “DOCETAXEL XRP6976” NCT02061631 ↗ |
| Action | Inhibit | “Docetaxel is an inhibitor of microtubule depolymerization” PMID 12586591 ↗ Feb 2003 |
| Modality | Small molecule | “Docetaxel is second generation taxoid” PMID 18626572 ↗ Jul 2008 |
| Route | Intravenous | “Patients receive mitoxantrone IV plus docetaxel IV over 1 hour on day 1.” NCT00002544 ↗ |
| Target | BCL2 | “Docetaxel inhibits the action of Bcl-2” NCT00452556 ↗ |